LOG IN

Treatment pathways and efficacy outcomes of patients with metastatic colorectal cancer (mCRC): a real-world prospective, longitudinal, cohort study (PROMETCO)

Data presented at the ESMO Congress 2025

Andrey Mitroshkin,1 Jean-Baptiste Bachet,2 Kalena Marti,3 Carmine Pinto,4 György Bodoky,5 Rocio Garcia-Carbonero,6 Elias Choucair,7 Bénédicte Chevallier,7 Adam Sullivan,8 Miriam Koopman.9

1. Klinikum Freudenstadt, AkademischesLehrkrankenhaus der UniversitätTübingen, Karl-von-Hahn-Strasse, 100, 72250 Freudenstadt, Germany; 2. Sorbonne Université, Service d’hépato-Gastro-Entérologie, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France; 3. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK; 4. Medical Oncology, Comprehensive Cancer Centre, AUSL – IRCCS di Reggio Emilia – Viale Risorgimento, 80 42123 Reggio Emilia, Italy; 5. Dél-Pesti Centrumkórház Szent László Telephely Albert Flórián út 5–7 1097 Budapest, Hungary; 6. Oncology Department, Hospital Universitario Doce de Octubre, Imas12, Departamento de Medicina, Universidad Complutense de Madrid (UCM), Avenida De Córdoba s/n, 28041 Madrid, Spain; 7. Servier, 35 rue Verdun, 92284 Suresnes, France; 8. Servier Pharmaceuticals, 200 Pier 4 Blvd, Boston, MA 02210, USA; 9. Department of Medical Oncology,University Medical Centre Utrecht, Utrecht University Heidelberglaan 100 3584 CX Utrecht, the Netherlands.

PROMETCO: Study background and aim

  • Data on real-world treatment of mCRC in 3L and beyond is limited to specific agents or to a single country1,2

  • With recent advances in mCRC therapies, such as trifluridine/tipiracil (FTD/TPI) ± bevacizumab, or fruquintinib, 3L treatment is no longer considered rescue therapy, with prolonged survival benefits being observed in clinical trials.3,4 However, there is little information on real-world treatment patterns or the impact of these treatment patterns, or other variables, on survival and other outcomes

  • PROMETCO (NCT03935763) is the first international, prospective, real-world study of treatment of patients with mCRC after two disease progressions since diagnosis5

Aim: To assess real-world treatment patterns and effectiveness in patients with mCRC

Inclusion criteria:5

  • Adults (aged ≥18 years) with a confirmed mCRC diagnosis

  • Two disease progressions since diagnosis of first metastasis

  • Willing to receive subsequent treatment

At enrollment (from March 2019 onwards), data for lines of therapy were collected retrospectively before two disease progressions and prospectively during 18-month follow-up period, including effectiveness data5

The four most frequently used treatment sequences were identified based on number of patients of each treatment group per line

Treatment pathway

Efficacy outcomes

Conclusions

3L, third-line; FTD/TPI, trifluridine/tipiracil; mCRC, metastatic colorectal cancer.
1. Taieb J, et al. BMC Cancer. 2023;23(1):94; 2. Weiss L, et al. ESMO Open. 2022;7(1):100391; 3. Prager GW, et al. N Engl J Med. 2023;388(18):1657–67; 4. Dasari A, et al. Lancet. 2023;402(10395):41–53; 5. Koopman M, et al. Future Oncol. 2022;18(11):1313–20.

back to top

 

back to top